Jefferies Maintains Buy on Legend Biotech Corporation (LEGN) March 2026

Jefferies maintained a Buy on Legend Biotech Corporation (LEGN) on March 10, 2026. This LEGN analyst rating highlights Jefferies’ confidence in ongoing Carvykti sales momentum and keeps a $69 price target on the shares. The firm’s action is a maintenance, not an upgrade or downgrade, and follows recent commercial progress tied to the therapy. Investors should read this as continued analyst conviction rather than a new endorsement or reversal.

LEGN analyst rating: Jefferies action on March 10, 2026

On March 10, 2026, Jefferies maintained its Buy rating on Legend Biotech Corporation (LEGN) and reiterated a $69 price target, citing Carvykti sales strength. StreetInsider reported the firm’s note at 12:01 PM ET and linked the call directly to commercial momentum for the therapy. source

Why Jefferies kept the Buy and the stated LEGN price target

Jefferies tied the maintained Buy to accelerating Carvykti prescription trends and revenue cadence and kept the $69 target as their valuation anchor. Investing.com coverage echoed the same rationale and noted the price target while restating sales-driven confidence. The firm’s stance implies expected upside from product adoption rather than short-term margin or trial outcome changes. source

Market reaction and short-term price movement after the LEGN analyst rating

The StreetInsider note timed the reiteration to market hours and the stock moved 0.8% (up $0.15) on the mention. Separate reporting shows shares trading near $19.41 in the same news cycle, reflecting the gap between current market price and Jefferies’ $69 target. Legend’s market cap sits at $1,806,263,936, which frames the firm’s price target as a multi-year growth expectation rather than an immediate comparator.

Historical analyst coverage and context for Legend Biotech Corporation

Jefferies has followed Legend through Carvykti’s commercial rollout and repeatedly cites sales momentum in notes. Recent press repeats the same Buy rating and price target across multiple outlets, showing steady analyst attention. That sustained coverage follows regulatory approvals and initial commercial data, moving analyst focus from trial outcomes to real-world sales execution.

What a maintained Buy means for investors

A maintained Buy is a signal of continued conviction, not a new bullish trigger. For investors, Jefferies’ move suggests confidence in execution and long-term upside tied to Carvykti adoption, while leaving room for near-term volatility. Use the LEGN analyst rating to weigh patience against current valuation and time horizon.

Meyka perspective and practical investor takeaways

Meyka AI rates LEGN with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects solid fundamentals relative to peers and the positive analyst stance, but it is not a guarantee. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Jefferies’ maintenance of a Buy on Legend Biotech Corporation (LEGN) on March 10, 2026 keeps the spotlight on Carvykti sales as the primary upside driver. The firm’s $69 price target signals multi-year revenue potential versus today’s near-term trading level around $19.41, and the stock’s market cap of $1,806,263,936 frames that gap. For investors, a maintained Buy means continued analyst confidence rather than a fresh upgrade; treat it as validation of execution rather than a catalyst for immediate price jumps. Use the LEGN analyst rating alongside Meyka AI’s B+ grade, company fundamentals, and your time horizon when sizing positions. Remember these views are analytical, not investment advice, and the ratings can change with sales trends, competitive shifts, or new data.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.